In particular, diABZI treatment in the lung during SARS-CoV-2 infection triggers a quick, transient antiviral response via type I IFNs, NF-κB–driven cytokine production, and lymphocyte activation, resulting in inhibition of viral replication and prevention of severe respiratory disease [18]. Here, NFKB1 is linked to respiratory system disorder.